Glucocorticoid receptor modulators to treat pancreatic cancer

Patent metadata

Field	Value
Publication number	US-10828280-B2
Application number	US-202016843727-A
Country	US
Kind code	B2
Filing date	Apr 8, 2020
Priority date	Sep 9, 2016
Publication date	Nov 10, 2020
Grant date	Nov 10, 2020

Abstract

The nonsteroidal SGRM may be a nonsteroidal compound comprising: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure. Pharmaceutical compositions comprising a chemotherapeutic agent and a GRM are disclosed. The GRM in such pharmaceutical compositions may be a nonsteroidal GRM, and may be a SGRM, such as a nonsteroidal SGRM. The nonsteroidal SGRM may comprise: a fused azadecalin structure; a heteroaryl ketone fused azadecalin structure; or an octahydro fused azadecalin structure.

First claim

What is claimed is:

1. A method of treating a subject hosting a non-ACTH-secreting pancreatic tumor, the method comprising:
Determining that the level of adrenocorticotrophic hormone (ACTH) in a sample taken from the subject is not significantly higher than the upper limit of the normal range for ACTH; and
Orally administering to the subject an effective amount of a chemotherapeutic agent and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator to reduce the tumor load of the pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a fused azadecalin structure.

2. The method of claim 1 , wherein the nonsteroidal selective glucocorticoid receptor modulator compound is the compound comprising a fused azadecalin structure having the formula:

3. The method of claim 1 , wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

4. The method of claim 1 , wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.

5. The method of claim 4 , wherein the chemotherapeutic agent is a taxane.

6. The method of claim 4 , wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

7. A method of treating a subject hosting a non-ACTH-secreting pancreatic tumor, the method comprising:
Determining that the level of adrenocorticotrophic hormone (ACTH) in a sample taken from the subject is not significantly higher than the upper limit of the normal range for ACTH; and
orally administering to the subject an effective amount of a chemotherapeutic agent and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator to reduce the tumor load of the pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising a heteroaryl ketone fused azadecalin structure.

8. The method of claim 7 , wherein the nonsteroidal selective glucocorticoid receptor modulator is the compound comprising a heteroaryl ketone fused azadecalin structure having the formula:

9. The method of claim 7 , wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

10. The method of claim 7 , wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.

11. The method of claim 10 , wherein the chemotherapeutic agent is a taxane.

12. The method of claim 10 , wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

13. A method of treating a subject hosting a non-ACTH-secreting pancreatic tumor, the method comprising:
Determining that the level of adrenocorticotrophic hormone (ACTH) in a sample taken from the subject is not significantly higher than the upper limit of the normal range for ACTH; and
orally administering to the subject an effective amount of a chemotherapeutic agent and an effective amount of a nonsteroidal selective glucocorticoid receptor modulator to reduce the tumor load of the pancreatic tumor, wherein the nonsteroidal selective glucocorticoid receptor modulator is a compound comprising an octahydro fused azadecalin structure.

14. The method of claim 13 , wherein the nonsteroidal selective glucocorticoid receptor modulator is the compound comprising an octahydro fused azadecalin structure having the formula:

15. The method of claim 13 , wherein the non-ACTH-secreting pancreatic tumor is an exocrine pancreatic tumor.

16. The method of claim 13 , wherein the chemotherapeutic agent is selected from the group consisting of taxanes, alkylating agents, topoisomerase inhibitors, endoplasmic reticulum stress inducing agents, antimetabolites, mitotic inhibitors and combinations thereof.

17. The method of claim 16 , wherein the chemotherapeutic agent is a taxane.

18. The method of claim 16 , wherein the chemotherapeutic agent is selected from the group consisting of nab-paclitaxel, 5-fluorouracil (5-FU), gemcitabine, cisplatin and capecitabine.

19. The method of claim 1 , further comprising administration of an anticancer treatment selected from surgery, radiation treatment, immunotherapy administration, growth factor inhibitor administration, and administration of an anti-angiogenesis factor.

20. The method of claim 7 , further comprising administration of an anticancer treatment selected from surgery, radiation treatment, immunotherapy administration, growth factor inhibitor administration, and administration of an anti-angiogenesis factor.

21. The method of claim 13 , further comprising administration of an anticancer treatment selected from surgery, radiation treatment, immunotherapy administration, growth factor inhibitor administration, and administration of an anti-angiogenesis factor.

Assignees

• Corcept Therapeutics Inc

Inventors

• Hunt Hazel
• Block Thaddeus S

Classifications

• A61P35/00

  Antineoplastic agents · CPC title

• A61P1/18

  for pancreatic disorders, e.g. pancreatic enzymes · CPC title

• A61K33/243 Primary

  Platinum; Compounds thereof · CPC title

• A61K31/7068

  having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid · CPC title

• A61K31/513

  having oxo groups directly attached to the heterocyclic ring, e.g. cytosine · CPC title